Jonathan P. Graham - 05 May 2026 Form 4 Insider Report for AMGEN INC (AMGN)

Reporting relationship: EVP & Gen. Counsel & Sec.
Issuer ticker: AMGN
Reported as of: 05 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 20:59:37 UTC
Prior SEC filing: 05 May 2026
Next SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan P. Graham

Key filing fact

Jonathan P. Graham filed Form 4 for AMGEN INC (AMGN) on 07 May 2026.

Key facts

This page summarizes Jonathan P. Graham's Form 4 filing for AMGEN INC (AMGN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 May 2026, 20:59.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001365306 Primary reporting owner

Graham Jonathan P

Relationship: EVP & Gen. Counsel & Sec.
Address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS
Signature: /s/ Jonathan P. Graham
Signature date: 06 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMGN transaction

Common Stock

Award

Transaction value
Shares: +2,609
Change %: +6.9%
Price: $0.000000^*
Shares after: 40,619
Date: 05 May 2026
Ownership: Direct
Footnotes: F1

AMGN transaction

Common Stock

Tax liability

Transaction value
Shares: -408
Change %: -1%
Price: $329.59^*
Shares after: 40,211
Date: 06 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMGN transaction Derivative

Nqso (Right to Buy)

Award

Transaction value
Shares: +17,022
Change %
Price: $329.59^*
Shares after: 17,022
Date: 05 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,022
Exercise price: $329.59
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Footnote F2

These shares include 370 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Footnote F3

These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.